A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2023-04-21
Adverse events
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-06-02 (study day 29); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-07-10 (study day 67); relationship: N
Grade 1 Nausea — outcome: UNKNOWN; onset 2023-08-12 (study day 100); relationship: Y
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-08-14 (study day 102); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-08-26 (study day 114); relationship: N
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-09-30 (study day 149); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-10-05 (study day 154); relationship: N
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-11-09 (study day 189); relationship: not assessed
Data queries
No data queries.